AveXis Inc. (AVXS) reported a fourth quarter net loss of $0.92 per share after the close Thursday, compared to the loss of $1.82 per share last year. The consensus estimate was for a loss of $0.80 per share.
The company also reported results from its Phase 1 clinical trial of AVXS-101 in spinal muscular atrophy Type 1. The results showed that the drug appears to have a favorable safety profile and to be generally well tolerated.
AveXis gapped open sharply higher Friday morning and is now up 11.51 at $84.29. The stock has been climbing for the past 3 weeks and has surged to a new high for the year.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org